We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | $-0.32 | — | — | $0 | — | 예정 |
Consensus PT $39.5 · 8 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 15. | Cantor Fitzgerald | — | 의견 유지 | Overweight → Overweight | — | Cantor Fitzgerald: Overweight |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Stored first · Google News · Yahoo Finance (English)
62,029,395 Common Stock of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
62,029,395 Common Stock of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. marketscreener.com
GHRS Stock Chart | GH RESEARCH PLC (NASDAQ:GHRS) - ChartMill
GHRS Stock Chart | GH RESEARCH PLC (NASDAQ:GHRS) ChartMill
RBC Capital Maintains GH Research(GHRS.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
RBC Capital Maintains GH Research(GHRS.US) With Buy Rating, Maintains Target Price $40 富途牛牛
Assessing GH Research (GHRS) Valuation After Positive Phase 2b Data For GH001 In Treatment Resistant Depression - simplywall.st
Assessing GH Research (GHRS) Valuation After Positive Phase 2b Data For GH001 In Treatment Resistant Depression simplywall.st
GH Research (NASDAQ: GHRS) highlights Phase 2b GH001 gains in treatment-resistant depression - Stock Titan
GH Research (NASDAQ: GHRS) highlights Phase 2b GH001 gains in treatment-resistant depression Stock Titan
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm (NASDAQ:GHRS) - Seeking Alpha
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm (NASDAQ:GHRS) Seeking Alpha